Marker Therapeutics Receives FDA Orphan Drug Designation for Its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer

Marker Therapeutics, Inc. announced that the US FDA Office of Orphan Products Development has granted Orphan Drug designation to MT-601, a multi-tumor-associated antigen-specific T cell product optimized for the treatment of patients with pancreatic cancer.